Vertex, BMS to test hepatitis C combo
This article was originally published in Scrip
Vertex Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration to test their experimental hepatitis C drugs together, another example that some companies need to partner to find the best combination for next-generation treatments of the virus.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.